Ignite Creation Date:
2024-05-05 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00525668
Status:
COMPLETED
Last Update Posted:
2021-07-29
First Post:
2007-09-04
Brief Title:
Sunphenon Epigallocatechin-gallate EGCg in Relapsing-remitting Multiple Sclerosis SuniMS Study
Sponsor:
Charite University Berlin Germany
Organization:
Charite University Berlin Germany
Study Overview
Official Title:
Sunphenon EGCg Epigallocatechin-gallate in Relapsing-remitting Multiple Sclerosis SuniMS Study
Status:
COMPLETED
Status Verified Date:
2021-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SuniMS
Brief Summary:
Hypothesis
Sunphenon a green tea extract containing 95 egcg given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination EDSS and MSFC
Sunphenon a green tea extract containing 95 egcg given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination EDSS and MSFC
Detailed Description:
This multicentric national study investigates the efficacy and safety of EGCG in patients with relapsing-remitting multiple sclerosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None